SIRT1 and amyotrophic lateral sclerosis: The first example is the case of NAD+/SIRT1 modulators that have shown capacity to increase mitochondrial OS resistance and protect against mitochondrial dysfunction in ALS models, as well as to significantly slow the disease progression in ALS patients, tested in a phase I clinical trial (NCT03489200) [253].